Key Takeaways Tempus AI now expects 2025 revenues of $1.25B and adjusted EBITDA of$5M, both raised from prior guidance. TEM's Q1 sales surged 75.4% and gross profit nearly doubled on lab gains and a higher data services mix. TEM's deals with AstraZeneca and Pathos and hereditary testing growth from Ambry Genetics drove guidance hike.Tempus AI (TEM) expects full-year 2025 revenues of $1.25 billion (up from the previous$1.24 billion guidance), which represents approximately 80% annual growth. The company ...